March 5th, UK: Up to £3 million is available for translational research projects that will enhance the UKRMP investment to help further realise the exciting potential of regenerative medicine research. In particular, this call is seeking to fund projects that address translational bottlenecks, such as safety science, and add value to the core programmes of the UKRMP. This opportunity is also aimed at helping new groups connect to the Platform, and it is anticipated that the majority of funding will be allocated to principal investigators (PIs) outside the current UKRMP Hubs.
The UK Regenerative Medicine Platform (UKRMP) was established in 2013 by the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC) and the Medical Research Council (MRC) to address the key translational challenges of regenerative medicine.
A £17 million tranche of funding currently supports the second phase of the Platform (UKRMP2), spanning the period 2018 to 2023. UKRMP2 is structured around three Hubs complemented by three cross-cutting immunological projects. Together, this interdisciplinary and integrated activity provides a world-leading programme to promote the development of regenerative therapies.
To enhance the impact of the Platform, the UKRMP sponsors, in partnership with JDRF (the type 1 diabetes research foundation) and the Multiple Sclerosis Society (MS Society), are inviting proposals for high-quality, collaborative research projects which will directly connect to the Hubs and build or extend Platform capabilities in addressing the key challenges in translational regenerative medicine.
Applications are welcome for projects which expand or link across core Hub science themes (such as pluripotent/engineered cells, cell environment, smart materials) and/or provide interconnectivity between cross-cutting elements (for example safety, manufacturing, quality control immunology) and Hub science themes.
For further details, please see the UKRMP Call for Proposals webpage.